-+ 0.00%
-+ 0.00%
-+ 0.00%

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil

Barchart·10/06/2026 06:30:00
Listen to the news

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.